Appendix 1: Detailed definitions of potential risk factors

Variable	Definition	Data source(s)	Exposure Start	Exposure End	Refs
1. TB-related fac	etors				
TB incidence in country of origin	TB Incidence (All TB forms/100,000 population) in the country of birth in the year of arrival to Canada	CIC / WHO TB Incidence Rates	Index date	End of study follow-up (i.e. no end of exposure)	(1,2)
BCG positive	Recorded as BCG positive OR Probable BCG positive based on birth year and birth country	TB Registry / Literature	Index date	End of study follow-up	(1,3,4)
Active TB Contact	Close contact includes household/Type 1 exposures	TB Registry	Date of contact	End of study follow-up	(1)
Abnormal chest x-ray	Result of chest x-ray (abnormal vs normal/unknown)	TB Registry	Date x-ray read	End of study follow-up	(1)
TST positive	First positive skin test (Recorded as positive test or induration≥10 mm)	TB Registry	Date skin test read	End of study follow-up	(1)
IGRA positive	First positive IGRA test	TB Registry	Date IGRA read	End of study follow-up	(1)
LTBI treatment completed	LTBI treatment completed (recorded as completed- satisfactory or completed- unsatisfactory) OR Estimated percent completion ≥80% of recommended doses based on TB drug dispensation records	TB Registry	30 days after date first LTBI drug dispensed	End of study follow-up	(1)
Referred by IRCC for post- landing surveillance	Date BCCDC received post- landing surveillance form	TB Registry	Date form received from IRCC	End of study follow-up	(1,5)
2. Medical Co-m	orbidities				
HIV/AIDS	HIV positive test or AIDS case recorded OR [≥1 hospital discharge records OR ≥2 MD billing records within 2 years with an ICD diagnosis code of HIV/AIDS: ICD9 042-044/ ICD10 B20-B24]*	BC HIV Registry / MSP/ DAD	90 days before first HIV positive test date or diagnosis date¶	End of study follow-up	(6,7)
Silicosis	[≥1 hospital discharge records OR ≥2 MD billing records within 2 years with an ICD diagnosis code of silicosis: ICD9 502, ICD10 J62]	MSP/ DAD	90 days before diagnosis date	End of study follow-up	-

Chronic kidney disease (CKD)	1+ chronic dialysis records in PROMIS OR 2+ physician billing records separated by at least 90 days with an MSP billing fee item code for dialysis (323, 324, 350-352, 355, 356, 358, 359, 361, 7598, 7599, 33723, 33750-33752, 33708, 33756, 33758, 33759, 33761, 77390, 77380) OR Any GFR<30 ml/min in PROMIS	BC Renal Agency (PROMIS)/ MSP	90 days before diagnosis date	End of study- follow-up	(8,9)
Cancer	Primary cancers of type=blood, head and neck, lung, or other solid organ (breast, gastrointestinal, genitourinary)	BC Cancer Registry	90 days before diagnosis date	5 years after cancer diagnosis date	(10,11)
Medical immuno- suppression	Treatment episodes: ≥1 dispensation records of immunosuppressant medications (See Appendix Table 2 for list of drugs included) For <i>steroid</i> treatment episodes: convert doses to prednisone equivalents, include when there was a minimum dispensation of 20mg daily for 14 days, within a 21 day period	Pharmanet	30 days after first drug dispense date	180 days after last drug dispense date	(12,13)
Diabetes	[1+ hospital discharge records OR 2+ MD billing records within 2 years with a diagnosis code of diabetes mellitus: ICD9 250.x / ICD10 E10.x-E14.x] <sup>‡</sup>	MSP/ DAD	90 days before diagnosis date	End of study- follow-up	(14,15)
Solid organ transplant	≥1 procedure code in hospital discharge records for transplant: CCP 455, 456, 495, 5899, 6249, 5352, 6484, 6483, 6759, 7792 / CCI: 1GR85, 1GT85, 1HY85, 1HZ85, 1NK85, 1NP85, 1OA85, 1OB85, 1OJ85, 1OK85, 1PC85, 1RB85)§	DAD	Transplant date	End of study- follow-up	(16,17)

IRCC=Immigration, Refugees, and Citizenship Canada; ICD=International Classification of Diseases; DAD=hospital discharge abstract database; MSP=Medical Services Plan physician billing; CCI=Canadian Classification of Interventions; CCP=Canadian Classification of Procedures; PPV=positive predictive value; NPV=negative predictive value

<sup>\*93.2%</sup> sensitivity, 99.4% specificity(6)

<sup>‡</sup> Pooled from 6 studies: 82.3% sensitivity, 92.9% specificity(15)

<sup>§</sup> CCI code for kidney transplantation: 98% sensitivity, 98% PPV(16)

<sup>¶</sup>When comorbidity identified using only MSP/DAD data, 'diagnosis date'=first date when algorithm is met (i.e. if rule requires 2 or more MSP billing records, take as the earliest date of the 2 billing records)

**Appendix 2: Immunosuppressive Drugs** 

Immunosuppressive drug   Progs included   Progs in AHFS class 10:00:00 (Antineoplastic Agents), excluding 'biologies' (see below in #3), Cyclophosphamide (see #4), Methotrexate (see #5), and Letrozole, Tamoxifen Citrate, and Tretinoin   AHFS class 92:36 (Disease modifying antirheumatic agents)   Adalimumab Etanercept Golimumab Infliximab   AHFS class 10:00:00 (Antineoplastic)   Alemtraumab Boverezomib   Cetuximab Boverezomib   Cetuximab Boverezomib   Cetuximab Boverezomib   Cetuximab Boverezomib   Eriotinib HCl Getftinb   Ipjitimumab Lapatimib Disoylate   Nilotinib HCl Pantinummab Regorafenib   Rituximab   AHFS class 92:20:00 (Biologic Response Modifier)   Natalizumab   AHFS class 92:240:00 (Biologic Response Modifier)   Natalizumab   AHFS class 92:44:00 (Immunosuppressive Agents)   Basiliximab   Basiliximab   Basiliximab   Basiliximab   AHFS class 92:44:00 (Immunosuppressive Agents)   Cyclophosphamide   AHFS class 92:44 (Immunosuppressive agents)   Cyclophosphamide   AHFS class 92:44 (Immunosuppressive agents)   Cyclophosphamide   AHFS class 92:44 (Immunosuppressive agents)   ALHS class 92:44 (Immunosuppressive agents)   ALIM class 9	Appendix 2: Immunosuppressive Drugs		
1. Cytotoxic (antineoplastic) neoplastic)  All drugs in AHFS class 10 000 00 (Antincoplastic Agents), excluding 'biologies' (see below in \$3), Cytophosphamide (see #4), Methorrexate (see #5), and Letrozole, Tamoxifen Citrate, and Tretinoin  AHFS class 22 36 (Disease medifying antirheumatic agents)  Adalimumab Etanercept Golimumab Infliximab Hestacizumab Bevacizumab Bortezomib Cetuxiinab Dabrafenib Mesylate Dasatinib Erlotinib HCl Geftinib Ipilimumab Lapatinib Ditosylate Nilotinib HCl Panitumumab Regorafenib Rituximab Ruxofitinib Phosphate Sorafenib Tosylate Sunifitiib Malate Trastuzumab Vemurafenib AHFS class 22 20 00 (Biologic Response Modifier) Natalizumab Vemurafenib AHFS class 92 24 00 (Immunosuppressive Agents) Basiliximab Belimumab AHFS class 92 24 (Immunosuppressive agents) Cyclophosphamide AHFS class 92 36 (Disease modifying antirheumatic agents) Cyclophosphamide AHFS class 92 36 (Disease modifying antirheumatic agents) Cyclophosphamide AHFS class 1000 (Antineoplastic Agents) Methorexate All drugs of class AHFS 60 00.00 (Gold Compounds) AHFS class 1000 (Antineoplastic Agents) AAHFS class 1000 (Antineoplastic Agents)		Drugs included	
Delow in #3), Cyclophosphamide (see #4), Methotrexate (see #5), and Letrozole, Tamoxifen Citrate, and Treitine in AIHFS class 92.36 (Disease modifying antirheumatic agents)   Adulmumab Etanercept Golimumab Infliximab Infliximab Infliximab Infliximab Infliximab Infliximab Bevacizumab Bovacizumab Bovacizumab Bovacizumab Bovacizumab Dabarafenib Mesylate Dasatinib Etoluinib HCl Gefütnib HCl Gefütnib HCl Panitumumab Regorafenib Rituximab Rituximab Rituximab Rituximab Rituximab Regorafenib Rituximab Regorafenib Rituximab Regorafenib Rituximab AIHFS class 92.000 (Biologic Response Modifier) Natalizumab Vermurafenib AIHFS class 92.2400 (Biologic Response Modifier) Natalizumab AIHFS class 92.4400 (Immunosuppressive Agents) Basiliximab Basiliximab Basiliximab Basiliximab Basiliximab AIHFS class 92.44 (Immunosuppressive Agents)   ABIA Colombia AIHFS class 92.36 (Disease modifying antirheumatic agents) Cyclophosphamide AIHFS class 92.36 (Disease modifying antirheumatic agents) Cyclophosphamide AIHFS class 92.36 (Disease modifying antirheumatic agents) Cyclophosphamide AIHFS class 92.44 (Immunosuppressive agents) Cyclophonolate Sirolimus Taerolimus AIHFS class 92.44 (Immunosuppressive agents) AIHFS class 92.44 (Immunosuppressiv			
Tamoxifen Citrate, and Tretinoin  AHFS class 92:36 (Disease modifying antirheumatic agents) Adalimumab Etanercept Golimumab Infliximab AHFS class 92:36 (Disease modifying antirheumatic agents) Adalimumab Etanercomib AHFS class 10:00:00 (Anti-neoplastic) Alemtuzumab Bortezomib Cetuximab Dabrafenib Mesylate Dasatinib Etfoltinib HCI Griftimib Ipilimumab Lapatinib Ditosylate Nilotinib HCI Panitrummab Ruxofitinib Plosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:00:00 (Biologic Response Modifier) Natalizumab AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakitra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamidc AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamidc AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamidc AHFS class 92:44 (Immunosuppressive agents) Cyclophonolate Sirolimus Tacrolimus AHFS class 10:00 (Antineoplastic Agents) Methorexate AHFS class 10:00 (Antineoplastic Agents) Methorexate AHFS class 10:00 (Antineoplastic Agents) Methorexate AHFS class 92:44 (Immunosuppressive agents)	,		
2. TNF-alpha inhibitors  AHES class 92:36 (Disease modifying antirheumatic agents) Adalimumab Etanercept Golimumab Infiximab Alexandrumah Bevacizumah Bevacizumah Bevacizumah Dabrafemb Mesylate Dasatinib Erlotnib HCl Geftinib Ipilimumab I apatinib Ditosylate Nitotinib HCl Panitumumab Regorafemih Ritusimab Ruxoitinib Phosphate Sorafenib Tosylate Suntinib Malate Trastuzumab Vemurafemih Malate Trastuzumab Vemurafemih AHES class 92:20:00 (Biologie Response Modifier) Natalizumab AHES class 92:240 (Immunosuppressive Agents) Basiliximab AHES class 92:44:00 (Immunosuppressive Agents) Cyclophosphamide AHES class 92:44 (Immunosuppressive agents) Cyclosponine Mycophenolate Sirolimus Tarcliss 01:20 (Sulfonamides) Sulfasalazine AHES class 92:44 (Immunosuppressive agents) Abatacept AHES class 92:45 (Disease modifying antirheumatic agents) Abatacept Anakinra AHES class 92:40 (Immunosuppressive agents) Cyclophosphamide AHES class 92:44 (Immunosuppressive agents) Cyclosponine Mycophenolate Sirolimus Tarcolimus AHES class 91:20 (Sulfonamides) Sulfasalazine AHES class 10:00 (Antincoplastic Agents) Methotrexate All drugs of class AHES 60:00:00 (Gold Compounds) AHES class 92:44 (Immunosuppressive agents) Azathioprine	neoplastic)		
Adalimumab Etanercept Golimumab Infliximab AHFS class 10:00:00 (Anti-neoplastic) Alemtuzumab Bevacizumab Bortezomib Cetuximab Dabrafenib Mesylate Dasatinib Erlotinib HCI Geftinib Ipilimumab Lapatinib Ditosylate Nilotinib HCI Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:34:40:00 (Immunosuppressive Agents) Basiliximab Belimumab AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Tellunomide AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Tellunomide AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamide AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 10:20 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamide			
Elancrecpt Golimumab Infliximab	2. TNF-alpha inhibitors		
Golimumab Infliximab  AHFS class 10:00:00 (Anti-neoplastic) Alemtuzumab Bevacizumab Bortezomib Cctuximab Dabrafenib Mesylate Dasatinib Erlotinib HCI Gefftinib Iplimumab I apatinib Ditosylate Nilotinib HCI Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sorafenib Tosylate Sunitinib Malate Trastuzumab AUS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 10:00 (Antineoplastic Agents) Abatacept Anakirra AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 10:00 (Antineoplastic Agents) Cyclopsoprine Mycophenolate Sirolimus Tarotlimus  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leftunomide AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 10:00 (Antineoplastic Agents) Cycloporine Mycophenolate Sirolimus Tarotlimus  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 10:00 (Antineoplastic Agents)		Adalimumab	
Infliximab   AHIFS class 10.00:00 (Anti-neoplastic)   Alemuzumab   Bevacizumab   Bortezomib   Cetuximab   Dabrafenib Mesylate   Dasatinib   Erlotinib HCl   Geftfinib   Ipilimumab   Lapatinib Ditosylate   Nilotinib HCl   Panitumumab   Regorafenib   Rituximab   Ruxolitinib Phosphate   Sorafenib   Rituximab   Ruxolitinib Phosphate   Sorafenib   Tosylate   Sunitinib Malate   Trastuzumab   Vernurafenib   AHFS class 92:20:00 (Biologic Response Modifier)   Natalizumab   AHFS class 92:20:00 (Biologic Response Modifier)   Natalizumab   AHFS class 92:24:00 (Immunosuppressive Agents)   Basiliximab   Belimumab   Belimumab   Belimumab   AHFS class 90:244:00 (Immunosuppressive Agents)   Cyclophosphamide   AHFS class 92:24 (Immunosuppressive agents)   Leflunomide   AHFS class 92:24 (Immunosuppressive agents)   Cycloporine   Mycophenolate   Sirolimus   Tacrolimus   Tacrolimus   Tacrolimus   AHFS class 10:00 (Antineoplastic Agents)   Methotexate   All drugs of class AHFS 60:00:00 (Gold Compounds)   AHFS class 92:34 (Immunosuppressive agents)   Azathioprine   Alters class 92:34 (Immunosuppressive agents)   Azathioprine   Azath		Etanercept	
Alertizumab Bevacizumab Bevacizumab Bevacizumab Bevacizumab Bevacizumab Beracomib Cetuximab Dabrafenib Mesylate Dasatinib Erlotinib HCI Geftinib Iplimumab Lapatinib Ditosylate Nilotinib HCI Panitumumab Regorafenib Rituximab Rusolitinib Phosphate Sorafenib Tosylate Suntitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:24:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 92:44:00 (Immunosuppressive Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) I. clunomide AHFS class 92:34 (Immunosuppressive agents) Cyclopsporine Mycophenolate Sirolimus Taerolimus  5. Dmards-low risk  AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:24 (Immunosuppressive agents) Arathioprine		Golimumab	
Alemtizumab Bevacizumab Bortezomib Cetuximab Dabrafenib Mesylate Dasatinib Erlotinib HCl Gefitinib Ipilimumab Lapatinib Ditosylate Nilotinib HCl Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHIFS class 92-2000 (Biologic Response Modifier) Natalizumab AHIFS class 92-236 (Disease modifying antirheumatic agents) Abatacept Anakinra AHIFS class 92-24+00 (Immunosuppressive Agents) Basiliximab Belimumab AHIFS class 92-24 (Immunosuppressive Agents) Cyclophosphamide AHFS class 92-24 (Immunosuppressive agents) Cyclophoriomate Sirolimus Tacrolimus Tacrolimus Tacrolimus Tacrolimus AIIFS class 10.00 (Antineoplastic Agents) Cycloptoriom Mycophenolate Sirolimus Tacrolimus Tacrolimus AIIFS class 10.00 (Antineoplastic Agents) Methotroxate AII drugs of class AHFS 60:00:00 (Gold Compounds) AIIFS class 92-24 (Immunosuppressive agents) Cycloproxate AII drugs of class AHFS 60:00:00 (Gold Compounds) AIIFS class 92-24 (Immunosuppressive agents) Cycloproxate AII drugs of class AHFS 60:00:00 (Gold Compounds) AIIFS class 92-24 (Immunosuppressive agents) Azathioprine		Infliximab	
Alemtizumab Bevacizumab Bortezomib Cetuximab Dabrafenib Mesylate Dasatinib Erlotinib HCl Gefitinib Ipilimumab Lapatinib Ditosylate Nilotinib HCl Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHIFS class 92-2000 (Biologic Response Modifier) Natalizumab AHIFS class 92-236 (Disease modifying antirheumatic agents) Abatacept Anakinra AHIFS class 92-24+00 (Immunosuppressive Agents) Basiliximab Belimumab AHIFS class 92-24 (Immunosuppressive Agents) Cyclophosphamide AHFS class 92-24 (Immunosuppressive agents) Cyclophorolate Sirolimus Tacrolimus Tacrolimus Tacrolimus Tacrolimus AHIFS class 10-00 (Antineoplastic Agents) Cycloptorine Mycophenolate Sirolimus Tacrolimus Tacrolimus AHIFS class 10-00 (Antineoplastic Agents) Methotrocate AHIFS class 10-00 (Antineoplastic Agents) Arathioprine	3. Other biologics	AHFS class 10:00:00 (Anti-neoplastic)	
Bortezomib Cetuximab Dabarafenib Mesylate Dasatinib Erlotinib HCl Geffitinib Ipilimumab Iapatinib Ditosylate Nilotinib HCl Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab AHFS class 92:44:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus  5. Dmards-low risk  AHFS class 10:00 (Antineoplastic Agents) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus Tacrolimus AHFS class 10:00 (Antineoplastic Agents) Methortexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 12:44 (Immunosuppressive agents) AAHfs class 92:44 (Immunosuppressive agents) AAHfs class 10:00 (Antineoplastic Agents) Methortexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Cetuximab Dabrafenib Mesylate Dasatinib Erlotinib HCI Geftinib Ipilimumab Lapatinib Ditosylate Nilotinib HCI Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus Tacrolimus AHFS class 10:00 (Antineoplastic Agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus Tacrolimus AHFS class 10:00 (Antineoplastic Agents) Methortexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Ayathloprine		Bevacizumab	
Dabrafenib Mesylate Dasatinib Erlotinib HCI Gefitinib HCI Gefitinib Ipilimumab Lapatinib Ditosylate Nilotinib HCI Panitumumab Regorafenib Rituximab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakima AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus Tacrolimus Tacrolimus AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine		Bortezomib	
Dabrafenib Mesylate Dasatinib Erlotinib HCI Gefitinib HCI Gefitinib Ipilimumab Lapatinib Ditosylate Nilotinib HCI Panitumumab Regorafenib Rituximab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakima AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus Tacrolimus Tacrolimus AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine		Cetuximab	
Dasatinib Erlotinib HCl Geftiinib Ipilimumab Lapatinib Ditosylate Nilotinib HCl Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:36 (Disease modifying antirheumatic agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  AHFS class 10:00 (Antineoplastic Agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  AHFS class 10:00 (Antineoplastic Agents) Oylosporine Mycophenolate Sirolimus Tacrolimus AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Erlotinib HCl Geftinib Ipilimumab Lapatinib Ditosylate Nilotinib HCl Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitininib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus Tacrolimus Tacrolimus Tacrolimus Tacrolimus AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Gefitinib Iplilimumab Lapatinib Ditosylate Nilotinib HCI Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:36 (Disease modifying antirheumatic agents) Basiliximab Belimumab AHFS class 90:44:00 (Immunosuppressive Agents) Basiliximab Belimumab AHFS class 90:44:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 90:246 (Disease modifying antirheumatic agents) Leflunomide AHFS class 90:44 (Immunosuppressive agents) Cyclophosphamide AHFS class 90:44 (Immunosuppressive agents) Cyclophosphamide AHFS class 90:45 (Disease modifying antirheumatic agents) Leflunomide AHFS class 90:45 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus Tacrolimus AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Ipilimumab Lapatinib Ditosylate Nilotinib HCI Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab Belimumab AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclophorine Mycophenolate Sirolimus Tacrolimus Tacrolimus  AHFS class 98:12:20 (Sulfonamides) Sulfasalazine AHFS class 90:12:20 (Sulfonamides) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Lapatinib Ditosylate Nilotinib HCI Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus Tacrolimus AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Nilotinib HC1 Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:236 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:244 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus AHFS class 10:00 (Antineoplastic Agents) Methotrexate Alf drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine		•	
Panitumumab Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Taerolimus  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Regorafenib Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Rituximab Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leftunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Ruxolitinib Phosphate Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 90:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Sorafenib Tosylate Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:36 (Disease modifying antirheumatic agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus  5. Dmards-low risk  AHFS class 10:00 (Antineoplastic Agents) Methotrexate AHFS class 09:12:20 (Sulfonamides) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Sunitinib Malate Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab 4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:36 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine		•	
Trastuzumab Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Vemurafenib AHFS class 92:20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
AHFS class 92;20:00 (Biologic Response Modifier) Natalizumab AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Natalizumab  AHFS class 92:36 (Disease modifying antirheumatic agents)  Abatacept  Anakinra  AHFS class 92:44:00 (Immunosuppressive Agents)  Basiliximab  Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents)  Cyclophosphamide  AHFS class 92:36 (Disease modifying antirheumatic agents)  Leflunomide  AHFS class 92:44 (Immunosuppressive agents)  Cyclosporine  Mycophenolate  Sirolimus  Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides)  Sulfasalazine  AHFS class 10:00 (Antineoplastic Agents)  Methotrexate  All drugs of class AHFS 60:00:00 (Gold Compounds)  AHFS class 92:44 (Immunosuppressive agents)  Azathioprine			
AHFS class 92:36 (Disease modifying antirheumatic agents) Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Abatacept Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Anakinra AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
AHFS class 92:44:00 (Immunosuppressive Agents) Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Basiliximab Belimumab  4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
4. Dmards-high risk  AHFS class 10:00 (Antineoplastic Agents) Cyclophosphamide AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Cyclophosphamide  AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide  AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine	4. Donarda biatariat		
AHFS class 92:36 (Disease modifying antirheumatic agents) Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine	4. Dmards-nigh risk		
Leflunomide AHFS class 92:44 (Immunosuppressive agents) Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
AHFS class 92:44 (Immunosuppressive agents)  Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Cyclosporine Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Mycophenolate Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Sirolimus Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Tacrolimus  5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
5. Dmards-low risk  AHFS class 08:12:20 (Sulfonamides) Sulfasalazine AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Sulfasalazine  AHFS class 10:00 (Antineoplastic Agents)  Methotrexate  All drugs of class AHFS 60:00:00 (Gold Compounds)  AHFS class 92:44 (Immunosuppressive agents)  Azathioprine			
AHFS class 10:00 (Antineoplastic Agents) Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine	5. Dmards-low risk		
Methotrexate All drugs of class AHFS 60:00:00 (Gold Compounds) AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
All drugs of class AHFS 60:00:00 (Gold Compounds)  AHFS class 92:44 (Immunosuppressive agents)  Azathioprine			
AHFS class 92:44 (Immunosuppressive agents) Azathioprine			
Azathioprine			
6. Steroids All drugs of AHFS class 68:04:00 (Hormones and substitutes adrenals) excluding			
value voi vivo (11011110110), vita linib), vita	6. Steroids	All drugs of AHFS class 68:04:00 (Hormones and substitutes, adrenals), excluding	

Fludrocortisone Acetate

AFHS=American Formulary Hospital Service code; Dmard=disease-modifying anti-rheumatic agent

## **References:**

- 1. Public Health Agency of Canada. Canadian Tuberculosis Standards 7th Edition. 2014. Available from: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/tb-canada-7/index-eng.php (Accessed 21-April-2016)
- 2. WHO World TB Database. [Internet] Available from: http://www.who.int/tb/country/data/download/en/ (Accessed 22-Apr-2016)
- 3. The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices [Internet]. Available from: http://www.bcgatlas.org/ (Accessed 22-Apr-2016)
- 4. World Health Organization. WHO vaccine-preventable diseases: monitoring system [Internet] 2016 Available from: http://apps.who.int/immunization\_monitoring/globalsummary (Accessed May 26, 2016).
- 5. Khan K, Hirji MM, Miniota J, Hu W, Wang J, Gardam M, et al. Domestic impact of tuberculosis screening among new immigrants to Ontario, Canada. *CMAJ*. 2015 Nov 3;187(16):E473–81.
- 6. Antoniou T, Zagorski B, Loutfy MR, Strike C, Glazier RH. Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection. *PLoS One*. 2011;6(6):e21748.
- 7. Nosyk B, Colley G, Yip B, Chan K, Heath K, Lima VD, et al. Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. *PLoS One*. 2013;8(1):e54416.
- 8. Grams ME, Plantinga LC, Hedgeman E, Saran R, Myers GL, Williams DE, et al. Validation of CKD and related conditions in existing data sets: A systematic review. *Am J Kidney Dis*. 2011 Jan;57(1):44–54
- 9. Ronksley PE, Tonelli M, Quan H, Manns BJ, James MT, Clement FM, et al. Validating a case definition for chronic kidney disease using administrative data. *Nephrol Dial Transpl.* 2012 May;27(5):1826–31.
- 10. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. *Clin Infect Dis.* 2006 Jun 1;42(11):1592–5
- 11. Wu CY, Hu HY, Pu CY, Huang N, Shen HC, Li CP, et al. Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-year population-based study. *Int J Tuberc Lung Dis*. 2011 Jan;15(1):125–30.
- 12. Brode SK, Jamieson FB, Ng R, Campitelli MA, Kwong JC, Paterson JM, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. *Thorax*. 2015 Jul;70(7):677–82.
- 13. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. *Ann Rheum Dis.* 2013 Jan;72(1):37–42
- 14. Health Canada. Responding to the Challenge of Diabetes in Canada: First Report of the National Diabetes Surveillance System (NDSS) Canada [Internet] 20133. Available from: http://www.phac-aspc.gc.ca/ccdpc-cpcmc/ndss-snsd/english/pubs reports/pdf/NDSS English Report FINAL.pdf (accessed 19-May-2016)
- 15. Leong A, Dasgupta K, Bernatsky S, Lacaille D, Avina-Zubieta A, Rahme E. Systematic review and meta-analysis of validation studies on a diabetes case definition from health administrative records. *PLoS One*. 2013;8(10):e75256.

- 16. Lam NN, McArthur E, Kim SJ, Knoll GA. Validation of kidney transplantation using administrative data. *Can J Kidney Health Dis.* 2015;2:20
- 17. Canadian Institute for Health Information (CIHI). Conversion Tables (for use with ICD-10-CA/CCI).[Internet] Available from: https://secure.cihi.ca/estore/productSeries.htm?pc=PCC85. (Accessed 16-May-2016)